pharma news

News

Rendering of planned Houston facility, via Eli Lilly

Lilly names Houston as site for $6.5bn API facility

Lilly has named Houston as the second of four locations for new manufacturing facilities that are central to a $27bn investment programme in the US.

News

David Hallal, Scholar Rock's chairman and chief executive

Manufacturing issues block FDA nod for Scholar Rock SMA drug

Unresolved issues at a manufacturing plant operated by Novo Nordisk have led to a complete response letter for Scholar Rock's SMA drug apitegromab.

News

Roche's oral SERD comes good in 2nd-line breast cancer trial

Roche has staked a claim to use its oral SERD giredestrant as a second-line therapy for breast cancer, regardless of a patient's ESR1 mutation status.

News

Jacopo Andreose, Angelini Pharma's chief executive

Angelini taps Sovargen for epilepsy drug in $550m deal

Angelini Pharma has licensed a preclinical-stage mTOR inhibitor from South Korean biotech Sovargen with potential for genetic forms of epilepsy.

News

BMS says it will set Cobenfy's UK price the same as the US

Bristol Myers Squibb's price tag for schizophrenia drug Cobenfy in the UK is a manifestation of Trump's most favoured nation drug pricing policy.

News

Alarm as Trump peddles unproven causes of autism

Medical groups have reacted with dismay after Trump linked childhood vaccinations and use of acetaminophen to autism.

Lilly names Houston as site for $6.5bn API facility

Manufacturing issues block FDA nod for Scholar Rock SMA drug

Roche's oral SERD comes good in 2nd-line breast cancer trial

Angelini taps Sovargen for epilepsy drug in $550m deal

BMS says it will set Cobenfy's UK price the same as the US

Alarm as Trump peddles unproven causes of autism

EU clears first drug therapy for rare disease cALD

Discover a new era of healthcare panel engagement: Grounded ...

pharma news

Editor's Picks